Why Eli Lilly (LLY) Shares Rose 6.63% on October 29, 2026 After Earnings

Eli Lilly (NYSE: LLY) shares rose 6.63% on Thursday, October 29, 2026, closing at $1,373.70 in U.S. dollars versus $1,288.30 on October 28. The $85.40 increase followed the pharmaceutical company's third-quarter earnings announcement. The clearest explanations for the market's positive response were 39% revenue growth, robust demand for Mounjaro and Zepbound, and a substantial increase in Lilly's 2026 sales forecast. Those are confirmed company disclosures; no public release can establish the precise motivation of every buyer.

This is a historical account of the October 29 session on the New York Stock Exchange, not a live stock quote. For context, LLY subsequently closed at $1,417.54 on Friday, October 30, another $43.84 or approximately 3.19% higher. The two gains belong to separate trading sessions and should not be confused.

What happened to LLY on October 29?

Both dates refer to NYSE regular sessions in New York, Eastern Daylight Time (EDT, UTC−04:00). The 4:00 p.m. New York closing bell corresponded to 20:00 UTC on each date. Lilly's own historical stock-price lookup is a primary reference for trading data. Figures here describe completed sessions rather than an intraday or after-hours quote.

To make the numbers practical, imagine Jordan, a hypothetical reader who sees the 6.63% headline after the closing bell. Jordan's first question is whether that percentage measures a move from the previous day's closing price or from the opening trade. It measures the close-to-close change: ($1,373.70 − $1,288.30) ÷ $1,288.30, rounded to 6.63%. Jordan's example is illustrative, not an account of an actual investor or trade.

Why did earnings provide a positive catalyst?

1. Revenue growth was broad but led by two major medicines

In its October 29 third-quarter earnings release, Lilly reported revenue of $24.397 billion, up 39% from $17.601 billion a year earlier. The company attributed much of the increase to its diabetes and obesity treatments, Mounjaro and Zepbound. Worldwide Mounjaro sales reached approximately $10.7 billion, up 65%, while Zepbound sales reached approximately $5.35 billion, up 49%.

The growth had an important qualification. Lilly said worldwide sales volume increased 53%, while realized prices declined 15%. Stronger demand helped offset that pricing pressure. For Jordan, this distinction matters more than merely reading the headline revenue percentage: more prescriptions and lower net selling prices can coexist.

2. Management raised the full-year revenue outlook

Lilly lifted its forecast for 2026 revenue to $91.0 billion–$92.0 billion, raising the midpoint by $5.5 billion. A higher revenue outlook can change expectations about a business's future earnings capacity, making it a plausible contributor to the share-price response. It does not prove that guidance alone caused the stock to rise.

The profit guidance requires a more careful reading. Lilly stated that underlying non-GAAP earnings-per-share guidance improved by $4.07 at the midpoint before the impact of significant acquired research charges. Those charges more than offset the underlying improvement, leaving the company's updated full-year non-GAAP EPS range at $35.00–$36.00. Calling every aspect of its EPS forecast an uncomplicated upgrade would be misleading.

3. Earnings held up despite large acquisition-related charges

Third-quarter reported EPS was $7.22, up 16% year over year, and non-GAAP EPS was $7.48, up 7%. Both measures included $4.57 per share in acquired in-process research and development (IPR&D) charges, compared with $0.71 in the year-earlier quarter. Unlike some companies' adjusted presentations, Lilly's disclosed non-GAAP EPS did not exclude these particular charges.

Another qualification is the approximately $900 million of quarterly revenue benefits that Lilly identified, including $410 million in Jardiance milestones and favorable revisions to rebate and discount estimates. The company said no further Jardiance milestones remain. These items should not automatically be treated as recurring growth. Jordan, in the hypothetical example, would separate them from the ongoing demand story before interpreting the quarter.

What else mattered beyond the headline numbers?

Lilly also highlighted progress across its drug portfolio, including regulatory developments in diabetes and oncology and positive clinical results for investigational retatrutide. The company described continued investment in manufacturing capacity and research. These announcements added context to the company's longer-term growth narrative, but the available evidence does not isolate any one development as the reason for the October 29 buying activity.

Lilly scheduled its earnings conference call for 10:00 a.m. New York EDT (UTC−04:00), or 14:00 UTC, on October 29, 2026, according to its official conference-call notice. That timing is separate from the 4:00 p.m. market close and from any publication or processing timestamp.

How should the October 30 follow-through be interpreted?

LLY's additional 3.19% gain on October 30 shows that the advance continued into the next regular session. It does not by itself prove that investors reached a new consensus about future profitability, nor does it guarantee that the price would continue rising afterward.

Returning to Jordan's illustrative example: a clear post-earnings review would distinguish three layers. The verified facts are the closing prices, reported results and revised outlook. The reasonable interpretation is that strong product demand and higher projected sales helped improve sentiment. The unknowns include each trader's motives, the durability of price and volume trends, and how expectations may evolve after the initial reaction.

Investors examining the full picture can compare Lilly's original earnings announcement with its SEC filings and historical share-price data, paying particular attention to realized pricing, manufacturing investment, acquisition-related costs and the difference between reported and non-GAAP results.

Bottom line: Lilly's October 29, 2026 rally was closely associated with a strong third-quarter report and a higher annual revenue forecast, led by Mounjaro and Zepbound. The confirmed close-to-close gain was 6.63%; October 30's 3.19% advance was a separate follow-through session. This explanation is informational and is not a recommendation to buy or sell LLY.